EPA:ALNEV - Euronext Paris - Matif - FR001400TG47 - Common Stock - Currency: EUR
Taking everything into account, ALNEV scores 1 out of 10 in our fundamental rating. ALNEV was compared to 71 industry peers in the Biotechnology industry. ALNEV has a bad profitability rating. Also its financial health evaluation is rather negative. ALNEV has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -149.13% | ||
ROE | -182.23% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Altman-Z | -4.88 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 0.64 | ||
Quick Ratio | 0.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | -1.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
EPA:ALNEV (6/3/2025, 7:00:00 PM)
0.003
0 (0%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 0.02 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 0 | ||
P/tB | 0 | ||
EV/EBITDA | -1.34 |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -149.13% | ||
ROE | -182.23% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | 0.72 | ||
Cap/Depr | 1.15% | ||
Cap/Sales | 27.36% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 0.64 | ||
Quick Ratio | 0.64 | ||
Altman-Z | -4.88 |